Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy
Roland Seiler(University of British Columbia), Peter C. Black(University of British Columbia), Mandeep Takhar(Genome British Columbia), Ewan A. Gibb(BC Cancer Agency), George N. Thalmann(University Hospital of Bern), Michiel S. van der Heijden(Zorginstituut Nederland), Ellen C. Zwarthoff(Erasmus MC), Nicholas Erho(Genome British Columbia), Kim van Kessel(Erasmus MC Cancer Institute), Gottfrid Sjödahl(Lund University), Joost L. Boormans(Erasmus MC), Jonathan L. Wright(Seattle University), Marc Dall’Era(University of California, Davis), Voleak Choeurng, Qiqi Wang, James Joshua Douglas, Brian Winters(University of Washington), Christine Buerki(Genome British Columbia), Bas W.G. van Rhijn(The Netherlands Cancer Institute), Elai Davicioni(Coherus BioSciences (United States))
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k